Jun Yu Selected Research

EphB6 Receptor

1/2012	Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer.
4/2010	The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer.
7/2009	The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jun Yu Research Topics

Disease

292	Neoplasms (Cancer) 12/2022 - 01/2002
87	Stomach Neoplasms (Stomach Cancer) 06/2022 - 01/2002
75	Carcinogenesis 11/2022 - 05/2002
55	Colorectal Neoplasms (Colorectal Cancer) 12/2022 - 06/2003
53	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 08/2004
51	Inflammation (Inflammations) 01/2022 - 07/2002
46	Neoplasm Metastasis (Metastasis) 10/2022 - 05/2003
43	Infections 01/2022 - 02/2001
38	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 03/2007
32	Adenocarcinoma 04/2022 - 04/2010
31	Fibrosis (Cirrhosis) 10/2022 - 05/2008
30	Fatty Liver 01/2022 - 04/2006
21	Ischemia 01/2020 - 01/2005
20	Liver Cirrhosis (Hepatic Cirrhosis) 12/2021 - 08/2007
18	Carcinoma (Carcinomatosis) 01/2020 - 08/2002
17	Non-alcoholic Fatty Liver Disease 01/2022 - 03/2010
16	Reperfusion Injury 01/2022 - 12/2005
16	Hypoxia (Hypoxemia) 01/2021 - 02/2002
16	Lung Neoplasms (Lung Cancer) 03/2020 - 07/2009
15	Colonic Neoplasms (Colon Cancer) 12/2021 - 11/2009
13	Atherosclerosis 01/2022 - 12/2007
12	Alcoholic Fatty Liver 06/2022 - 08/2008
12	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 05/2007
12	Necrosis 01/2021 - 07/2007
10	Liver Neoplasms (Liver Cancer) 06/2022 - 01/2006
9	Adenoma (Adenomas) 04/2021 - 12/2008
8	Dysbiosis 12/2022 - 01/2018
8	Pulmonary Fibrosis (Fibrosing Alveolitis) 10/2022 - 01/2020
8	Cysts 01/2022 - 10/2007
8	Insulin Resistance 01/2022 - 04/2008
8	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 04/2013
8	Cerebral Hemorrhage 02/2021 - 09/2004
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 07/2009
7	COVID-19 01/2022 - 01/2021
7	Pain (Aches) 01/2022 - 02/2006
7	Leukemia 12/2021 - 02/2009
7	Mitochondrial Diseases (Mitochondrial Disease) 10/2021 - 01/2016
7	Brain Injuries (Brain Injury) 10/2021 - 01/2016
7	Neoplasms, Cystic, Mucinous, and Serous 01/2020 - 04/2009
7	Metaplasia 01/2019 - 05/2002

Drug/Important Bio-Agent (IBA)

93	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2002
66	Biomarkers (Surrogate Marker)IBA 06/2022 - 04/2007
55	MicroRNAs (MicroRNA)IBA 01/2022 - 09/2008
48	Messenger RNA (mRNA)IBA 01/2022 - 01/2002
44	Biological ProductsIBA 01/2022 - 08/2003
37	CytokinesIBA 12/2022 - 07/2007
34	DNA (Deoxyribonucleic Acid)IBA 12/2022 - 06/2003
29	Pharmaceutical PreparationsIBA 04/2022 - 01/2003
22	RNA (Ribonucleic Acid)IBA 12/2022 - 03/2011
20	CateninsIBA 10/2022 - 01/2011
18	Transcription Factors (Transcription Factor)IBA 01/2022 - 06/2003
17	Choline (Choline Chloride)IBA 01/2022 - 04/2007
16	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 01/2005
15	Small Interfering RNA (siRNA)IBA 10/2022 - 07/2007
15	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 09/2003
14	Methionine (L-Methionine)FDA Link 12/2021 - 04/2007
13	Therapeutic UsesIBA 01/2022 - 09/2010
12	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 04/2006
11	CholesterolIBA 01/2022 - 02/2009
11	EnzymesIBA 01/2022 - 07/2012
11	LigandsIBA 01/2022 - 06/2005
11	Long Noncoding RNAIBA 01/2022 - 11/2016
11	InterleukinsIBA 01/2022 - 07/2007
11	LipidsIBA 12/2021 - 02/2008
10	ChemokinesIBA 10/2022 - 05/2007
10	Phosphotransferases (Kinase)IBA 01/2021 - 03/2007
10	Interleukin-6 (Interleukin 6)IBA 04/2018 - 04/2006
10	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2010 - 05/2003
9	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2021 - 01/2016
9	Peptides (Polypeptides)IBA 01/2020 - 07/2003
9	PPAR gammaIBA 01/2019 - 01/2006
9	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 07/2002
8	Bleomycin (Blenoxane)FDA LinkGeneric 10/2022 - 04/2011
8	NF-kappa B (NF-kB)IBA 01/2022 - 11/2005
8	InterferonsIBA 01/2022 - 04/2012
8	Indicators and Reagents (Reagents)IBA 10/2021 - 09/2010
8	ChromatinIBA 01/2021 - 01/2012
8	Amino Acids FDA Link 01/2020 - 01/2005
7	eel ventricular natriuretic peptideIBA 01/2021 - 02/2002
7	AzoxymethaneIBA 01/2021 - 12/2012
7	CarcinogensIBA 01/2021 - 01/2005
7	CathelicidinsIBA 10/2020 - 04/2010
7	Gemcitabine FDA Link 12/2017 - 07/2008
7	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2016 - 02/2006
7	LuciferasesIBA 09/2016 - 08/2008
7	Alanine Transaminase (SGPT)IBA 03/2012 - 07/2007
6	Interleukin-10 (Interleukin 10)IBA 12/2022 - 07/2007
6	Adenosine Triphosphate (ATP)IBA 04/2022 - 04/2012
6	SaltsIBA 02/2022 - 07/2005
6	InflammasomesIBA 01/2022 - 01/2016
6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2006

Therapy/Procedure

76	Therapeutics 08/2022 - 07/2003
21	Liver Transplantation 01/2021 - 06/2004
17	Drug Therapy (Chemotherapy) 04/2022 - 09/2008
10	Pancreatectomy 01/2022 - 06/2010
9	Neoadjuvant Therapy 07/2022 - 01/2019
8	Immunotherapy 06/2022 - 09/2017
8	Ligation 10/2020 - 01/2009
7	Transplantation 01/2022 - 08/2010
6	Adjuvant Chemotherapy 01/2022 - 10/2010